Mounjaro 15mg KwikPen

Mounjaro 15 mg KwikPen – Tirzepatide for Type 2 Diabetes and Weight Management

Mounjaro 15 mg KwikPen is a prescription pre-filled injection pen containing Tirzepatide 15 mg per 0.6 mL dose. It is administered once weekly to help manage type 2 diabetes and, in eligible adults, support medically supervised weight management. Tirzepatide activates glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors, also known as GIP and GLP-1 receptors. It helps improve blood-sugar control by supporting insulin release when glucose levels are elevated, reducing excess glucagon release, slowing stomach emptying, and regulating appetite. Each multidose KwikPen contains four fixed doses of 15 mg. The pen contains a total of 60 mg of tirzepatide in 2.4 mL. Mounjaro 15 mg is a high maintenance strength and should be used only after gradual dose escalation according to the prescribing healthcare professional’s instructions.

Key Features

• Contains Tirzepatide: A dual GIP and GLP-1 receptor agonist.
• 15 mg Per Dose: Each injection delivers 15 mg of tirzepatide in 0.6 mL.
• Four Weekly Doses: Each multidose KwikPen provides four fixed doses.
• Once-Weekly Treatment: Administered on the same day each week.
• Supports Blood-Sugar Control: Used with diet and physical activity for type 2 diabetes.
• Supports Weight Management: Helps regulate appetite and food intake in eligible adults.
• Maximum Adult Strength: The 15 mg dose is not intended as the starting dose.

Active Ingredient

• Tirzepatide 15 mg per 0.6 ml dose

Uses

• Management of insufficiently controlled type 2 diabetes alongside diet and physical activity.
• May be used alone when metformin is unsuitable or alongside other diabetes medicines.
• Weight loss and long-term weight management in eligible adults with obesity.

How to Use

• Use Mounjaro 15 mg KwikPen exactly as prescribed by your healthcare professional.
• Inject one prescribed dose once weekly on the same day each week.
• It may be administered at any time of day, with or without food.
• Inject it under the skin of the abdomen, thigh, or upper arm.
• Do not inject it into a vein or muscle.
• Rotate the injection site with every weekly dose.
• Use a new compatible pen needle for every injection.
• Prime the KwikPen before every dose according to the supplied instructions.
• Turn the dose knob until it stops and the number “1” appears in the dose window.
• Hold the dose knob down as instructed to ensure the complete dose is delivered.
• Remove and safely discard the needle immediately after each injection.
• Never share the KwikPen or needles with another person.
• Do not count clicks, divide the fixed dose, or attempt to withdraw leftover medicine from the pen.
• Discard the pen after four weekly doses, even if some liquid remains inside.

Precautions

• Mounjaro 15 mg is not a starting dose and should be reached only through the prescribed dose-escalation schedule.
• Nausea, vomiting, and diarrhoea may cause dehydration and reduced kidney function. Maintain appropriate fluid intake.
• The risk of low blood sugar may increase when used with insulin or a sulfonylurea medicine.
• Patients with diabetic eye disease should report sudden or worsening changes in vision.

Possible Side Effects

• Nausea.
• Diarrhoea.
• Vomiting.
• Constipation.
• Abdominal pain or discomfort.
• Indigestion, bloating, or acid reflux.
• Reduced appetite.
• Burping or increased intestinal gas.
• Injection-site redness, itching, or irritation.

Storage

• Before first use, store in a refrigerator between 2°C and 8°C.
• Do not freeze or use a pen that has been frozen.
• Keep the pen in its original packaging to protect it from light.
• After first use, the pen may be stored at a temperature not exceeding 30°C for up to 30 days.
• Keep the pen cap attached when the pen is not being used.
• Never store the pen with a needle attached.

Legal Disclaimer: Mounjaro 15 mg KwikPen is a prescription medicine and the highest available adult maintenance strength. It should be used only after gradual dose escalation and under the supervision of a qualified healthcare professional. Eligibility, dose selection, treatment duration, and concurrent diabetes therapy must be determined by the prescribing doctor. This information is provided for educational purposes only and should not replace professional medical advice, diagnosis, treatment, or the official patient leaflet and KwikPen instructions.